What Is CBG?
CBG (Cannabigerol) is one of the non-psychoactive cannabinoids produced by the cannabis plant that is gaining popularity because of its potential therapeutic benefits. Patients have reported that it can help with anxiety, depression, pain, insomnia, and other conditions. This cannabinoid is often referred to as the “Mother of Cannabinoids” because CBD, THC and CBC are derived from CBGA, the acid form of CBG. As the plant develops, CBGA converts into CBDA, THCA, or CBCA with the help of enzymes. When CBGA, CBDA, THCA and CBCA are heated, they decarboxylate and turn into CBG, CBD, THC, and CBC.
Most cannabis strains on the market today have small amounts of CBG. By the time the plant is harvested, most of the CBGA has converted into THCA or CBDA. Some strains have more CBG than others, and the timing of harvest can affect the amount of it in a strain. There are now a few CBG dominant strains that are being grown that also contain either THC or CBD. Unfortunately, research on the therapeutic benefits of CBG is limited. However, the studies that have been conducted show that this cannabinoid may help with various health conditions and symptoms.
Potential Therapeutic Benefits
Strains With CBG
This cannabinoid is found in small amounts in most cannabis strains with around 1% CBGA and CBG combined. We have a new unique strain called White CBG that has large amounts of CBG without THC or CBD. If you have never tried CBG, this strain may be a great way to see if it works well for you. Check out our menu for current offerings and keep an eye out for the CBG content in our products.
- Brierley, D. I., Samuels, J., Duncan, M., Whalley, B. J., & Williams, C. M. (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology, 233(19-20), 3603–3613. https://doi.org/10.1007/s00213-016-4397-4
- de Meijer, E.P.M., Hammond, K.M. The inheritance of chemical phenotype in Cannabis sativa L. (II): Cannabigerol predominant plants. Euphytica 145, 189–198 (2005). https://doi.org/10.1007/s10681-005-1164-8
- Gugliandolo, A., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2018). In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid. International journal of molecular sciences, 19(7), 1992. https://doi.org/10.3390/ijms19071992
- Lah, T. T., Novak, M., Pena Almidon, M. A., Marinelli, O., Žvar Baškovič, B., Majc, B., Mlinar, M., Bošnjak, R., Breznik, B., Zomer, R., & Nabissi, M. (2021). Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma. Cells, 10(2), 340. https://doi.org/10.3390/cells10020340
- Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., Petrocellis, L. D., Laezza, C., Portella, G., Bifulco, M., & Marzo, V. D. (2006, September 1). Antitumor activity of Plant cannabinoids with emphasis on the effect of Cannabidiol on human BREAST CARCINOMA. Journal of Pharmacology and Experimental Therapeutics. https://jpet.aspetjournals.org/content/318/3/1375.long.
- Nachnani, R., Raup-Konsavage, W. M., & Vrana, K. E. (2021). The Pharmacological Case for Cannabigerol. The Journal of pharmacology and experimental therapeutics, 376(2), 204–212. https://doi.org/10.1124/jpet.120.000340
- Navarro, G., Varani, K., Reyes-Resina, I., Sánchez de Medina, V., Rivas-Santisteban, R., Sánchez-Carnerero Callado, C., Vincenzi, F., Casano, S., Ferreiro-Vera, C., Canela, E. I., Borea, P. A., Nadal, X., & Franco, R. (2018). Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Frontiers in pharmacology, 9, 632. https://doi.org/10.3389/fphar.2018.00632
- Robaina Cabrera, C. L., Keir-Rudman, S., Horniman, N., Clarkson, N., & Page, C. (2021). The anti-inflammatory effect of cannabidiol and cannabigerol alone, and in combination. Pulmonary pharmacology & therapeutics, 69, 102047. https://doi.org/10.1016/j.pupt.2021.102047
- Rock, E. M., Goodwin, J. M., Limebeer, C. L., Breuer, A., Pertwee, R. G., Mechoulam, R., & Parker, L. A. (2011). Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology, 215(3), 505–512. https://doi.org/10.1007/s00213-010-2157-4
- Russo, E. B., Cuttler, C., Cooper, Z. D., Stueber, A., Whiteley, V. L., & Sexton, M. (2021). Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis and cannabinoid research, 10.1089/can.2021.0058. Advance online publication. https://doi.org/10.1089/can.2021.0058